Triptorelin

Introduction Overview

Generic Name

triptorelin

Brand Name

Trelstar

Dosage Form

intramuscular powder for injection (3.75 mg/month; 11.25 mg/3 months; 22.5 mg/6 months)

Drug Class

Gonadotropin releasing hormones; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Triptorelin administered as Trelstar is supplied as an intramuscular depot injection in a powder form to be reconstituted with sterile water prior to administration. Upon IM injection, the drug forms a depot at the site of injection, allowing for slow and sustained release into systemic circulation. Absorption is characterized by a gradual increase of plasma triptorelin levels resulting in steady-state concentrations achieved in a time frame corresponding to the dosing interval. The depot formulation leads to continuous exposure over 4, 12, or 24 weeks depending on the specific dosage form (3.75 mg monthly, 11.25 mg quarterly, or 22.5 mg semiannually). Clinical pharmacokinetic studies indicate that peak plasma concentrations are reached approximately 4 to 12 hours following administration, with detectable levels sustained throughout the dosing period.

Distribution:
Triptorelin demonstrates moderate plasma protein binding, although exact figures are not well defined. Given its peptide nature, distribution is largely confined to the extracellular fluid compartment. The volume of distribution is consistent with peptide hormones of similar molecular weight. Triptorelin does not readily cross the blood-brain barrier although it acts centrally on the pituitary to exert its mechanism of action. It is unlikely to accumulate in adipose tissue due to hydrophilic characteristics. The depot injection limits fluctuations in plasma levels, maintaining sustained exposure necessary for therapeutic efficacy.

Metabolism:
Triptorelin is metabolized predominantly by proteolytic degradation, yielding smaller peptide fragments and amino acids. These metabolites are inactive and further processed via normal peptide metabolic pathways. The metabolism occurs primarily in plasma and peripheral tissues, with little involvement of hepatic cytochrome P450 enzymes, thereby reducing the potential for hepatic drug interactions. The exact metabolic pathways have not been fully elucidated but are consistent with other synthetic GnRH analogs.

Elimination:
Elimination of triptorelin and its metabolites is primarily achieved via renal excretion. The peptide fragments formed after metabolism are water-soluble and renally cleared. The half-life of triptorelin following IM depot administration varies depending on the formulation, with prolonged half-lives consistent with depot release. Renal impairment may theoretically affect clearance, but clinical data are limited. Because triptorelin is administered as a depot injection, systemic clearance is less relevant for dosing adjustments. Overall, the pharmacokinetic profile supports its use as a long-acting GnRH analogue with sustained therapeutic levels over weeks to months.

Dosage Forms

Available Dosage Forms:
Trelstar is provided as an intramuscular powder for injection in a Mixject single-dose delivery system, which contains two components: a vial of sterile triptorelin powder and a pre-filled syringe containing sterile water for injection. This reconstitution system facilitates preparation and administration by healthcare professionals. The available dosage strengths are:
- 3.75 mg vial for monthly administration
- 11.25 mg vial for administration every three months
- 22.5 mg vial for administration every six months

Dosages for Adults and Adolescents:
Trelstar dosing is tailored for palliative treatment of advanced prostate cancer in adult males. The recommended dosing regimens are:
- 3.75 mg administered intramuscularly every 4 weeks
- 11.25 mg administered intramuscularly every 12 weeks (3 months)
- 22.5 mg administered intramuscularly every 24 weeks (6 months)
Dosage strength choice should be based on the desired dosing frequency. Importantly, the dose strengths are not additive due to their differing release characteristics and must be used independently according to approved schedules.

Specific Patient Populations:
Trelstar is intended for use primarily in adult male patients with advanced prostate cancer. Use in pediatric or female populations is contraindicated or lacks sufficient safety data. Dose adjustments based on renal or hepatic impairment are not routinely required due to depot formulation and non-hepatic metabolism; however, caution is advised. There is an absence of data in patients with severe renal or hepatic dysfunction. The long-acting depot injection requires adherence to dosing intervals to maintain therapeutic efficacy. Pregnant women must not use Trelstar as it can cause fetal harm. The drug may impact male fertility and thus appropriate counseling and contraceptive measures should be considered.

Mechanism Of Action

Trelstar (triptorelin) is a synthetic gonadotropin-releasing hormone (GnRH) agonist that exerts its primary action by interacting with GnRH receptors located in the anterior pituitary gland. Upon administration, triptorelin initially stimulates these receptors, causing a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This results in a temporary increase in circulating testosterone levels, known as the flare phenomenon, which may exacerbate symptoms of hormone-sensitive conditions such as prostate cancer during the initial treatment phase.

With continuous administration, sustained stimulation of GnRH receptors leads to receptor desensitization and downregulation. This receptor downregulation results in suppression of LH and FSH release from the pituitary, culminating in a marked decrease in gonadal steroidogenesis, particularly testosterone production from the testes in males. In effect, this causes a medical castration state by reducing circulating testosterone levels to castrate or near-castrate levels, which is therapeutically beneficial for treating advanced prostate cancer, a disease that requires testosterone for growth and proliferation.

At the cellular and molecular level, triptorelin mimics the endogenous GnRH with modifications that prolong receptor binding and reduce enzymatic degradation, thereby allowing for sustained bioactivity. The suppression of testosterone production inhibits androgen receptor activation in prostate cancer cells, leading to decreased tumor cell proliferation and induced apoptosis. Comparative clinical studies highlight triptorelin's effectiveness in maintaining low testosterone levels similar to other GnRH agonists like leuprolide and goserelin, but with differing pharmacokinetic profiles allowing for various dosing intervals.

Research evidence from clinical trials has demonstrated the efficacy of triptorelin in reducing PSA levels and ameliorating symptoms related to advanced prostate cancer. The pharmacodynamic profile aligns well with the desired therapeutic outcome of androgen deprivation therapy (ADT). Ongoing studies continue to explore triptorelin's long-term benefits and role in combination with other therapies for castration-resistant prostate cancer. Overall, Trelstar's mechanism embodies a strategic hormonal manipulation targeting the hypothalamic-pituitary-gonadal axis to achieve therapeutic suppression of androgen-dependent malignancies.

Pharmacological Actions

Acts as a GnRH agonist stimulating pituitary GnRH receptors.
Induces initial transient elevation of LH, FSH, and testosterone levels (flare effect).
Causes downregulation/desensitization of pituitary GnRH receptors with continuous administration.
Suppresses LH and FSH secretion, leading to decreased gonadal testosterone production.
Induces a chemical castration state, lowering serum testosterone to castrate levels.
Exerts indirect antineoplastic effects by depriving prostate cancer cells of androgen stimulation.
Modifies the hypothalamic-pituitary-gonadal axis hormonal balance.
Reduces androgen receptor activation in hormone-sensitive prostate cancer cells.
Prolonged duration of action due to depot IM formulation.
Minimal hepatic metabolism limits cytochrome P450-mediated drug interactions.
Demonstrates similar efficacy to other GnRH agonists like leuprolide and goserelin.
Used in androgen deprivation therapy to slow progression of advanced prostate cancer.
May influence pituitary-gonadal axis feedback mechanisms.
Contributes to reduction of prostate-specific antigen (PSA) levels over treatment course.
Potentially affects other hormonal axes indirectly due to systemic androgen depletion.

Therapeutic Or Clinical Uses

Palliative treatment of advanced hormone-dependent prostate cancer in men.
Androgen deprivation therapy (ADT) for control of prostate cancer symptoms.
Reducing testosterone levels to slow progression of testosteronedependent prostate tumors.
Management of urinary symptoms related to prostate cancer progression.
Temporary suppression of testicular steroidogenesis in hormone-sensitive malignancies.
Alternative to surgical castration in prostate cancer management.
Part of combination therapy regimens including anti-androgens for prostate cancer.
Use in patients unfit for or refusing orchiectomy for testosterone suppression.
Control of bone pain and other systemic symptoms secondary to prostate cancer.
Potential off-label use under specialist discretion for other sex hormone dependent conditions.
Preoperative hormonal management prior to prostatectomy in prostate cancer.
Reduction of PSA levels as a biomarker indicative of therapeutic response.
Medical management during initial flare phase to control transient worsening of symptoms.
Used in long-term management to maintain castrate testosterone levels.
Treatment of patients with metastatic prostate cancer to improve quality of life.

Side Or Adverse Effects

Injection site reactions including pain, swelling, redness, and itching.
Hot flashes due to decreased androgen levels disrupting thermoregulation.
Erectile dysfunction, impotence, reduced libido, and difficulty achieving orgasm.
Bone pain and arthralgia possibly related to tumor flare or hormone deprivation.
Headache associated with central hormonal effects.
Vaginal bleeding reported rarely in female exposure (contraindicated in pregnancy).
Symptoms of cold or flu including nasal congestion, cough, sore throat, and ear pain.
Transient worsening of prostate cancer symptoms during initial therapy (flare phenomenon).
Increased risk of mental health disturbances such as mood changes, irritability, depression, or aggression.
Seizures or convulsions reported rarely; caution in patients with seizure disorders.
Cardiovascular symptoms including chest pain or pressure, with potential arrhythmias in susceptible individuals.
Neurologic symptoms such as numbness, weakness, balance problems, or vision disturbances due to increased intracranial pressure.
Hyperglycemia and metabolic changes including increased thirst, urination, and hunger.
Rare but severe allergic reactions like urticaria, rash, and airway swelling.
Loss of bone mineral density and increased risk of osteoporosis with long-term androgen deprivation.

Precautions

Use cautiously in patients with a history of mental illness or mood disorders due to risk of behavioral changes.
Monitor patients with seizure disorders or those on medications that may lower seizure threshold.
Avoid use in women who are pregnant or may become pregnant; male patients should use effective contraception as well.
Assess cardiovascular risk prior to initiation due to potential QT prolongation and arrhythmias.
Monitor blood glucose levels, particularly in diabetic patients, to detect hyperglycemia.
Evaluate bone mineral density periodically, especially with long-term treatment, to mitigate osteoporosis risk.
Consider urinary tract obstruction or bladder outlet obstruction before initiation due to possible urinary retention.
Monitor electrolyte levels (potassium, magnesium) in patients with known imbalances.
Careful use in patients with history of stroke or ischemic heart disease.
Inform patients regarding possible initial symptom worsening and counsel to report worsening signs promptly.
Avoid abrupt discontinuation; follow scheduled dosing to maintain stable hormone levels.
Use caution in patients with known tumor or vascular lesions of the brain.
Advise patients about potential fertility impact and discuss sperm preservation if desired.
Regularly assess for signs of increased intracranial pressure (headache, vision changes).
Ensure trained healthcare professional administers IM injection due to risk of injection site complications.

Warnings

Contraindicated in pregnancy due to risk of fetal harm.
May cause an initial hormone surge leading to temporary worsening of prostate cancer symptoms (flare phenomenon).
Risk of new or worsening mental health disorders including depression, aggression, or irritability.
Possible occurrence of seizures; immediate medical attention required if convulsions occur.
Increased intracranial pressure can develop, manifesting as severe headaches, visual disturbances, and nausea.
May cause hyperglycemia and exacerbate underlying diabetes mellitus.
Potential cardiovascular events including chest pain and arrhythmias in predisposed patients.
Undesired bone loss with prolonged androgen deprivation therapy.
Serious allergic reactions including anaphylaxis have been reported rarely.
Use caution in patients predisposed to electrolyte imbalances or arrhythmias to avoid QT prolongation.
The drug does not treat the underlying prostate cancer but manages symptoms by hormone suppression.
Patients should be monitored for worsening or new neurological symptoms.
Avoid use in patients with known hypersensitivity to GnRH analogues such as leuprolide or goserelin.
Injection site infections or abscess formation can occur if aseptic technique is compromised.
Ensure patients have access to immediate medical care in case of adverse reactions.

Contraindication

Known hypersensitivity or allergy to triptorelin or related GnRH analogues like leuprolide and goserelin.
Pregnancy due to teratogenicity and potential fetal harm.
Women of childbearing potential not using effective contraception.
Severe uncontrolled cardiovascular disease where hormone fluctuations may pose risk.
Patients with history of severe hypersensitivity reactions to injectable peptides.
Concurrent seizure disorders not adequately controlled with medication (use with caution).
Severe hepatic or renal impairment lacks safety data, use cautiously or avoid.
Any condition in which transient testosterone surge may pose severe risk not manageable with monitoring.
Known active intracranial tumors or vascular lesions without stabilization.
Unresolved urinary tract obstruction if risk of acute retention is unmanageable.
Patients unable to comply with regular intramuscular dosing schedules.
Overdose or misuse due to depot formulation risks prolonged adverse effects.
Use in pediatric populations due to lack of established safety and efficacy.
Known hypersensitivity to any component of the Mixject delivery system.
Previous severe adverse reactions to GnRH agonists.

Drug Interactions

Concurrent use with drugs that prolong QT interval may increase risk of arrhythmias; caution advised.
Antidepressants that lower seizure threshold may interact, increasing risk of seizures.
Concurrent use with other hormonal therapies may affect therapeutic outcomes.
Coadministration with antiandrogens may be indicated during initial flare to manage symptoms.
Diabetes medications may require dose adjustments due to hyperglycemia risk.
No significant cytochrome P450 mediated interactions due to metabolism by proteolysis.
Possible pharmacodynamic interactions with drugs affecting pituitary hormone regulation.
Concomitant use of corticosteroids may influence hormonal balance and efficacy.
Interactions with anticoagulants have not been documented but monitor for bleeding abnormalities.
Herbal supplements affecting hormone levels (e.g., phytoestrogens) should be used cautiously.
Vitamin D and calcium supplementation may be needed due to risk of osteoporosis.
Diuretics causing electrolyte imbalances may enhance cardiac risks.
Drugs lowering seizure threshold such as tricyclic antidepressants or antipsychotics require caution.
No notable interactions with over-the-counter vitamins but full medication disclosure recommended.
Potential interactions with other peptide drugs metabolized similarly remain to be fully elucidated.

Preparations Of The Drug

Trelstar is prepared as a sterile powder intended for intramuscular injection after reconstitution.
Supplied as a Mixject single-dose system with a vial of powder and a pre-filled sterile water syringe.
Available in 3 dosage strengths: 3.75 mg (1-month duration), 11.25 mg (3-month duration), and 22.5 mg (6-month duration).
Reconstitution should be performed aseptically immediately prior to administration.
Injection is administered intramuscularly in the buttock, alternating sites periodically to minimize local irritation.
Each vial is intended for single use; any remaining solution must be discarded after administration.
Needles and syringes should be used once and disposed of in puncture-proof containers following local regulations.
Store the powder and assembled product at room temperature, avoiding moisture and heat; do not freeze.
Packaging includes clear instructions for preparation, handling, and disposal.
Use immediately after reconstitution to ensure drug stability and potency.
No preservatives are present; risk of contamination necessitates strict sterile technique.
Healthcare professionals should monitor for injection site reactions post administration.
Disposal of unused product and materials should strictly follow biohazard and pharmaceutical waste guidelines.
Availability through prescription and administration under medical supervision due to injection route.
Patient education materials accompany the product to guide safe handling and expectations.